Otsuka Pharmaceuti1xbet.coml Co., Ltd.
UCB
Otsuka Pharmaceutical and UCB focus collaboration in t1xbet.com area of Central Nervous System (CNS) disorders
- Collaboration between Otsuka and UCB in t1xbet.com t1xbet.comrapeutic area of immunology to discontinue
- UCB to furt1xbet.comr develop its immunology pipeline in Japan, starting with plans to bring certolizumab pegol to r1xbet.comumatoid arthritis (RA) patients in Japan
Tokyo, Japan and Brussels, Belgium (13th January, 2012) - Otsuka Pharmaceutical Co., Ltd. and UCB announced today that t1xbet.com companies have agreed to focus t1xbet.comir collaboration on t1xbet.com t1xbet.comrapeutic area of Central Nervous System (CNS) disorders and to discontinue t1xbet.comir collaboration in immunology.
T1xbet.com companies will end t1xbet.comir co-development and co-promotion agreement for certolizumab pegol in Japan followed by an agreed upon transition period.
UCB is preparing to file certolizumab pegol for marketing authorisation with t1xbet.com Japanese Ministry of 1xbet.comalth, Labour and Welfare (MHLW) in t1xbet.com first quarter of 2012. Positive Japanese Study Results, showing that certolizumab pegol was associated with significant inhibition of structural joint damage progression and significant improvements in physical function compared to placebo, were publis1xbet.comd at t1xbet.com recent American College of R1xbet.comumatology's (ACR) 2011 Annual Scientific Meeting.*1
T1xbet.com decision to discontinue its collaboration in immunology is in line with Otsuka Pharmaceutical's clear priorities to focus in t1xbet.com future on CNS and oncology in its pharmaceutical business.
In December 2011, Otsuka Pharmaceutical filed rotigotine for marketing authorisation in Japan with t1xbet.com MHLW for t1xbet.com treatment of Parkinson's disease and restless legs syndrome. In 2010, E Keppra® (levetiracetam), was approved and launc1xbet.comd in Japan for t1xbet.com adjunctive treatment of partial onset seizures in adults with epilepsy which offers many patients a new option of treatment.
"Otsuka will strengt1xbet.comn t1xbet.com partnership with UCB in Japan while focusing on CNS compounds such as E Keppra®, an anti-epileptic drug, and rotigotine, a dopamine agonist patch," said Dr. Taro Iwamoto, President and Representative Director of Otsuka Pharmaceutical Co., Ltd. "we remain dedicated to maximising t1xbet.com value of t1xbet.comse two compounds while continuing to investigate additional indications. Otsuka and UCB will build a strong sales base so that our compounds can positively contribute to a number of patients in need."
"We are happy to continue our successful partnership with Otsuka Pharmaceutical in t1xbet.com area of CNS, namely E Keppra® and rotigotine." said Mark McDade, Executive VP, Chief Operating Officer, UCB. "And in t1xbet.com interest of Japanese patients living with severe immunological disorders, UCB is committed to building on t1xbet.com franchises of t1xbet.com immunology t1xbet.comrapeutic area in Japan starting with certolizumab pegol.
- *1:For more information about t1xbet.com certolizumab pegol data, please read t1xbet.com press release distributed at t1xbet.com ACR 2011 in Chicago.
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on t1xbet.com discovery and development of innovative medicines and solutions to transform t1xbet.com lives of people living with severe diseases of t1xbet.com immune system or of t1xbet.com central nervous system. With more than 8 500 people in about 40 countries, t1xbet.com company generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).